Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Journal of Biological Chemistry, 39(288), p. 28009-28020, 2013

DOI: 10.1074/jbc.m113.501346

Links

Tools

Export citation

Search in Google Scholar

Active Glutaminase C Self-assembles into a Supratetrameric Oligomer That Can Be Disrupted by an Allosteric Inhibitor*

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

The phosphate-dependent transition between enzimatically inert dimers into catalytically-capable tetramers has long been the accepted mechanism for the glutaminase activation. Here, we demonstrate that activated Glutaminase C (GAC) self-assembles into a helical, fiber-like double-stranded oligomer and propose a molecular model, consisting of seven tetramer copies per turn per strand interacting via the N-terminal domains. The loop L321RFNKL326 is projected as the major regulating element for self-assembly and enzyme activation. Furthermore, the previously identified in vivo lysine acetylation (Lys311 in humans, Lys316 in mouse) is here proposed as an important down-regulator of super-oligomer assembly and protein activation. BPTES (Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide), a known glutaminase inhibitor, completely disrupted the higher-order oligomer, explaining its allosteric mechanism of inhibition via tetramer-stabilization. A direct correlation between the tendency to self-assemble and the activity levels of the three mammalian glutaminase isozymes was established, with GAC being the more active enzyme while forming the longest structures. Lastly, the ectopic expression of a fiber-prone super-active GAC mutant in MDA-MB 231 cancer cells provided considerable proliferative advantages to transformed cells. These findings yield unique implications for the development of GAC-oriented therapeutics targeting tumor metabolism.